A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies
Phase 2 Completed
40 enrolled 15 charts
Upfront Chimeric Antigen Receptor T-Cell to Upgrade Response in Multiple Myeloma
Phase 2 Completed
40 enrolled 21 charts
A Study of CC-95266 in Participants With Relapsed and/or Refractory Multiple Myeloma
Phase 1 Completed
130 enrolled
Propylene Glycol-Free Melphalan HCl (EVOMELA®) in Combination With Fludarabine and Total Body Irradiation Based Reduced Intensity Conditioning for Haploidentical Transplantation
Phase 2 Completed
43 enrolled 9 charts
FT576 in Subjects With Multiple Myeloma
Phase 1 Completed
31 enrolled
Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation
Phase 1/2 Completed
34 enrolled 18 charts
UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep
Phase 2 Completed
15 enrolled 15 charts
A Study of JNJ-68284528 Out-of-Specification (OOS) for Commercial Release in Participants With Multiple Myeloma
Phase 2 Completed
86 enrolled 19 charts
Reduced Intensity Chemotherapy and Radiation Therapy Before Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies
Phase 2 Completed
35 enrolled 14 charts
Dose Escalation Trial of WT1-specific Donor-derived T Cells Following T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Relapsed/Refractory Multiple Myeloma
Phase 1 Completed
29 enrolled
Umbilical Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With Hematologic Disease
Phase 2 Completed
135 enrolled 19 charts
Haploidentical Stem Cell Transplant with Prophylactic Natural Killer DLI for Lymphoma, Multiple Myeloma, and CLL
Phase 1 Completed
20 enrolled
FluBuATG
Phase 1 Completed
20 enrolled
Allo HSCT Using RIC for Hematological Diseases
Phase 2 Completed
156 enrolled
Immunotherapy With BCMA CAR-T Cells in Treating Patients With BCMA Positive Relapsed or Refractory Multiple Myeloma
Phase 1 Completed
28 enrolled 18 charts
KarMMa-4
Phase 1 Completed
13 enrolled
Reduced Intensity Conditioning Transplant Using Haploidentical Donors
Phase 2 Completed
25 enrolled 10 charts
Allogeneic Hematopoietic Stem Cell Transplantation With Ixazomib for High Risk Multiple Myeloma (BMT CTN 1302)
Phase 2 Completed
57 enrolled 22 charts
Shorter Course Tacro After NMA, Related Donor PBSCT With High-dose Posttransplant Cy for Hard-to-Engraft Malignancies
Phase 2 Completed
117 enrolled 27 charts
HLA-Compatible Related or Unrelated Donors With CD34+ Enriched, T-cell Depleted Peripheral Blood Stem Cells Isolated by the CliniMACS System in the Treatment of Patients With Hematologic Malignancies
Phase 2 Completed
422 enrolled 19 charts
Busulfan, Melphalan, Fludarabine and T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation Followed by Post Transplantation Donor Lymphocyte Infusions
Phase 2 Completed
66 enrolled 13 charts
HaploOnly
Phase 1 Completed
74 enrolled
Calcineurin Inhibitor-Free GVHD Prevention Regimen After Related Haplo PBSCT
Phase 1 Completed
32 enrolled 12 charts
Modified Stem Cell Transplant Procedure to Treat Patients With Blood and Immune System Cancers
Phase 2 Completed
62 enrolled 15 charts
T-cells Expressing an Anti-SLAMF7 CAR for Treating Multiple Myeloma
Phase 1 Completed
13 enrolled 15 charts
Combined Haploidentical-Cord Blood Transplantation for Adults and Children
Phase NA Completed
87 enrolled 10 charts
Chemotherapy Followed by Allogeneic Stem Cell Transplantation for Hematologic Malignancies
Phase NA Completed
18 enrolled 7 charts
Mismatched Transplantation Using High-dose Post-transplant Cyclophosphamide
Phase 2 Completed
176 enrolled 18 charts
Stem Cell Transplant for Patients With Blood Malignancy Using Donors and Less Toxic Chemotherapy With CAMPATH 1H
Phase 1/2 Completed
40 enrolled
Study of T Cells Targeting B-Cell Maturation Antigen for Previously Treated Multiple Myeloma
Phase 1 Completed
30 enrolled 13 charts
Melphalan+Bortezomib as a Conditioning Regimen for Autologous and Allogeneic Stem Cell Transplants in Multiple Myeloma
Phase 2 Completed
124 enrolled 13 charts
Reduced Intensity Double Umbilical Cord Blood Transplantation
Phase 2 Completed
33 enrolled 19 charts
Fludarabine Based Conditioning for Allogeneic Transplantation for Advanced Hematologic Malignancies
Phase NA Completed
100 enrolled 10 charts
Shorter Course Tacrolimus After Nonmyeloablative, Related Donor BMT With High-dose Posttransplantation Cyclophosphamide
Phase 1 Completed
127 enrolled
Total Marrow Irradiation for Refractory Acute Leukemia
Phase 1 Completed
12 enrolled
Rasburicase in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer or Other Disease Undergoing Donor Stem Cell Transplant
Phase 1 Completed
46 enrolled 11 charts
MINI HEME
Phase 2 Completed
25 enrolled
Study of Unrelated Cord Blood Transplantation Using Tacrolimus and Sirolimus
Phase 2 Completed
32 enrolled
Nonmyeloablative Allogeneic Stem Cell Transplantation From HLA-Matched Unrelated Donor for the Treatment of Hematologic Disorders
Phase 2 Completed
25 enrolled
Allo BMT Using Matched Related/Unrelated Donors With FluBu and HiCY
Phase 1/2 Completed
92 enrolled 5 charts
MINIALO-VELCAD
Phase 2 Completed
30 enrolled
FM 140 vs FM100 Study in Patients With Multiple Myeloma
Phase 2 Completed
52 enrolled 7 charts
Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation of Patients With Hematological Diseases
Phase 1/2 Completed
24 enrolled
Cellular Therapy With Cord Blood Cells
Phase 2 Completed
31 enrolled 6 charts
Study of KIR-Ligand Mismatched Haplo-Identical Natural Killer Cells Transfused Before Autologous Stem Cell Transplant
Phase 1 Completed
10 enrolled